pembrolizumab for Esophageal Neoplasms Malignant

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Esophageal Neoplasms Malignant+1 More
pembrolizumab - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new cancer treatment combination to see what effects it has on patients with esophagogastric cancer.

Eligible Conditions
  • Esophageal Neoplasms Malignant
  • Malignant Neoplasm of Stomach

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Esophageal Neoplasms Malignant

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 6 months

6 months
Progression free survival

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for Esophageal Neoplasms Malignant

Side Effects for

Pembrolizumab
17%Decreased appetite
16%Fatigue
16%Dyspnoea
16%Cough
15%Anaemia
12%Constipation
12%Hypothyroidism
11%Nausea
11%Diarrhoea
11%Rash
10%Weight decreased
10%Asthenia
10%Pyrexia
10%Alanine aminotransferase increased
10%Back pain
10%Pruritus
9%Arthralgia
9%Aspartate aminotransferase increased
8%Chest pain
8%Vomiting
7%Pneumonia
7%Headache
7%Haemoptysis
6%Hyperthyroidism
6%Upper respiratory tract infection
6%Blood alkaline phosphatase increased
6%Musculoskeletal pain
6%Hypertension
5%Oedema peripheral
5%Pain in extremity
5%Myalgia
5%Insomnia
4%Pneumonitis
4%Dizziness
3%Stomatitis
3%Malaise
2%Death
2%Pleural effusion
2%Pulmonary embolism
2%Leukopenia
1%Neutrophil count decreased
1%Pericardial effusion
1%Colitis
1%White blood cell count decreased
1%Platelet count decreased
1%Autoimmune hepatitis
1%Bronchitis
1%Sepsis
1%Interstitial lung disease
1%Pulmonary haemorrhage
1%Respiratory failure
1%Neutropenia
1%Thrombocytopenia
1%Neuropathy peripheral
1%Peripheral sensory neuropathy
This histogram enumerates side effects from a completed 2022 Phase 3 trial (NCT02220894) in the Pembrolizumab ARM group. Side effects include: Decreased appetite with 17%, Fatigue with 16%, Dyspnoea with 16%, Cough with 16%, Anaemia with 15%.

Trial Design

1 Treatment Group

Pembrolizumab, trastuzumab,capecitabine/cisplatin
1 of 1
Experimental Treatment

37 Total Participants · 1 Treatment Group

Primary Treatment: pembrolizumab · No Placebo Group · Phase 2

Pembrolizumab, trastuzumab,capecitabine/cisplatinExperimental Group · 6 Interventions: Oxaliplatin, 5-Fluorouracil, cisplatin, trastuzumab, pembrolizumab, capecitabine · Intervention Types: Drug, Drug, Drug, Drug, Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Oxaliplatin
FDA approved
Fluorouracil
FDA approved
Cisplatin
FDA approved
Trastuzumab
FDA approved
Pembrolizumab
FDA approved
Capecitabine
FDA approved

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 6 months

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,821 Previous Clinical Trials
584,310 Total Patients Enrolled
32 Trials studying Esophageal Neoplasms Malignant
7,773 Patients Enrolled for Esophageal Neoplasms Malignant
Yelena Janjigian, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
9 Previous Clinical Trials
827 Total Patients Enrolled
3 Trials studying Esophageal Neoplasms Malignant
91 Patients Enrolled for Esophageal Neoplasms Malignant

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have disease that can be evaluated radiographically.
Patients may have received no prior chemotherapy for Stage IV disease.
You must be between the ages of 18 and 65 years old.
Demonstrate adequate organ function as defined below

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 27th, 2021

Last Reviewed: October 14th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.